non-small cell lung cancer
Conditions
Interventions
experimental group:Carrelizumab 200mg q3w
Sponsors
Anhui Chest Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18~75 years old, male or female; 2. Patients with unresectable and unresectable stage IIIA-IIIC non-small cell lung cancer confirmed by histopathology or cytology; 3. The disease has not progressed after concurrent chemoradiotherapy with platinum-containing regimen (at least 2 cycles); 4. ECOG PS score 0-1 points; 5. Expected survival period >= 6 months; 6. The main organ functions are normal, and there are no patients with severe blood, lung, liver, kidney, bone marrow and other functional abnormalities. Laboratory inspections meet the following requirements: (1) Hemoglobin (Hb) >= 90 g/L; (2) White blood cells (WBC) >=3.0x10^9/L; neutrophil count (NEUT) >=1.5x10^9/L; (3) Platelet (PLT)>=100x10^9/L (4) Liver function (aspartate aminotransferase AST or alanine aminotransferase ALT) level <= 2.5 times the upper limit of normal (ULN); renal function (serum creatinine sCr) level <= 1.5 times the upper limit of normal (ULN); (5) Total bilirubin (TBIL) <= 1.5 times the upper limit of normal (ULN); (6) Urine protein and urine occult blood <2+; fecal occult blood <2+. 7. History of pneumonia or interstitial pneumonia without hormone control; 8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up; 9. The investigator believes that the treatment can be beneficial.
Exclusion criteria
Exclusion criteria: 1. Those who have proved allergic to the test drug and/or its excipients; 2. Subjects who have received or are receiving additional chemotherapy, radiation therapy, targeted or immunotherapy; 3. Suffering from any active autoimmune disease or history of autoimmune disease; 4. Suffering from congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA >= 500 IU/mL), hepatitis C (positive hepatitis C antibody, and high HCV-RNA) (the lower limit of detection of the analytical method) or co-infection of hepatitis B and C; or a history of organ transplantation; 5. There are clinical symptoms or diseases of the heart that are not well controlled, such as: (1) Heart failure of NYHA grade 2 or above; (2) Unstable angina; (3) Myocardial infarction occurred within 1 year; 6. Pregnant or lactating women; 7. Patients who are judged by the researchers to be unsuitable for inclusion in this study; 8. Those with internal medical system diseases and psychiatric diseases who are not suitable for chemotherapy; 9. Those with acute infection requiring antibiotic treatment; 10. Patients who have participated in clinical trials of other drugs within four weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year survival rate; | — |
Countries
China
Contacts
Public ContactMin Xuhong
Anhui Chest Hospital
Outcome results
None listed